several biochemically unique G6PD variants. 2 To further characterize the G6PD variant, kinetic measurements were performed using leukocyte-derived G6PD (Table 1) . These results led us to conclude that the kinetic properties of the mutant enzyme were only slightly altered. Hence, G6PD deficiency in this athlete appears to be mainly due to the mutant protein's instability, in particular in erythrocytes ( Figure 1 ).
Heavy exercise can accelerate the generation of reactive oxygen species (ROS), exceeding the capacity of antioxidant defenses. 3 Because this may result in hemolysis and muscle For personal use only. on April 8, 2017 . by guest www.bloodjournal.org From degeneration, it has been postulated that G6PD-deficient persons with red blood cell enzyme activities less than 15% of normal should avoid prolonged high-intensity physical exercise. 4 Two recent studies concluded that G6PD-deficient persons are able to perform mild to moderate exercise without higher oxidative stress than G6PD-nondeficients. 5, 6 Of particular interest are 2 case reports describing adverse effects of exercise on G6PD-deficient persons. The first describes a 20-year-old G6PD-deficient man who was hospitalized for myalgia and myoglobinuria after intense exercise; he carried the same G6PD variant as our case. 7 The second is a 30-year-old pentathlon-trained athlete with G6PD deficiency who suffered from loss of consciousness and pigmenturia during the last meters of a 12-km competitive run. 8 Contrary to both these reports, our athlete showed no more severe signs of myalgia, myoglobinuria, or hemoglobinuria than other elite long-distance runners, although residual activity in erythrocytes was approximately 9%, and the calculated activity 9 in muscle cells was 13% of normal. We postulate that the athlete described here has developed a unique balance between his G6PD deficiency and exercise-induced disturbances of blood glutathione and lipid peroxidation that allows him to perform strenuous exercise. 
To the editor:
In vivo-activated CD103 ؉ Foxp3 ؉ Tregs: of men and mice
We read with interest the article by Zhao et al 1 on the specific abilities of murine CD103 ϩ T regulatory (Treg) cells to ameliorate ongoing chronic graft-versus-host disease (cGVHD). The authors report here that only in vivo-activated effector/memory-like Tregs that express high amounts of the integrin ␣E (CD103) are able to efficiently control the disease in a murine model based on allogeneic transfer of DBA/2 donor cells into BALB/c hosts. In conclusion, the authors suggest that the infusion of human CD103 ϩ Tregs might also ameliorate cGVHD in patients, so that the reported findings may offer a new strategy for the treatment of cGVHD patients. In principle, the use of effector/memory-like Treg cells may be indeed beneficial also in human therapy. We would like to point out, however, that the markers for this Treg subset are not compatible between humans and mice. CD103 is a well-established marker for murine effector/memory-like Treg cells, which have been activated in vivo by antigen in a specific context. In naive mice, up to 30% of CD25 ϩ FOXP3 ϩ lymphocytes in fact express CD103. 2 In contrast to this, cells with this marker are virtually absent among human CD25 high Foxp3 ϩ Treg cells. It is expressed by less than 5% of human CD25 high Foxp3 ϩ Treg cells in various tissues, including blood. [3] [4] [5] [6] This applies also for ␤7, the integrin ␤-chain binding to CD103, which is only poorly expressed by human Treg cells. 3, 7 Although in CD4 ϩ T cells CD103 expression can be induced by different stimuli in vitro, 5,8 a significant expression of CD103 on human CD4 ϩ cells with regulatory potential ex vivo was reported only in tonsils, here, however, mostly on CD25 Ϫ cells. 5 Given the different expression of CD103 by Foxp3 ϩ Tregs in mice and humans, it is highly questionable whether the results obtained with murine CD103 ϩ Tregs can be translated 1:1 into a clinical setting. There is little doubt that equivalent cell subsets exist in humans and mice, and that effector/memory-like Treg cells fulfill analog functions in both species. Addressing these cells, however, requires considering species-specific differences. In humans, effector/memory-like Treg cells (T REM ) are better defined by markers such as CCR6 or CD39. 9,10
